Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,124Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M31.4EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book4.810-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.5PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M49,500,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XBI

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XBIFirst Eagle Investment 2016-09-30 Sold Out $55.11 - $68.83
($61.74)
$ 63.112%Sold Out0
XBIFirst Eagle Investment 2016-03-31 Buy $45.73 - $70.2
($52.16)
$ 63.1121%New holding18,150
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XBI is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XBI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Brown, ArthurDirector, Senior Officer 2016-11-08Buy25,000$0.2822439.29view
BACH, WENDYSenior Officer 2016-11-08Sell3,549$48.0631.32view
BACH, WENDYSenior Officer 2016-11-08Buy4,619$48.0831.26view
BACH, WENDYSenior Officer 2016-11-08Sell1,070$48.0631.32view
Miller, James MichaelSenior Officer 2016-11-08Buy5,000$4.31367.67view
Omni-Lite Industries Canada InIssuer 2016-11-08Buy2,300$1.653724.85view
PAMPLIN, Ann-Marie MichelleDeemed Insider - 6 Months before becoming Insider 2016-11-08Buy13,000$0.1348446.15view
Glazier, Patrick L.Director 2016-11-08Buy100,000$0.1444978.57view
Sutton, Brayden RobertDirector 2016-11-08Buy5,000$0.2822439.29view
Reilly, Robert BruceSenior Officer 2016-11-08Sell155,000$0.06105083.33view

Quarterly/Annual Reports about XBI:

    News about XBI:

    Articles On GuruFocus.com
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
    Baidu: A Great Opportunity for Long-Term Investors Dec 04 2016 
    Intel's Future Still Looks Bright Dec 04 2016 
    CBS Corp: Navigating the Media Challenges Well Dec 04 2016 
    How General Electric Is Re-Positioning Itself for Dividend Growth Dec 04 2016 
    Warren Buffett Shares His Thoughts About the Election Dec 04 2016 
    Weekly Top Insider Buys Highlight for the Week of Dec. 2 Dec 04 2016 
    Jokes, Analogies and Anecdotes in Warren Buffett’s Shareholder Letters Dec 04 2016 
    Low-Priced Retail Stocks Gurus Shopped for Ahead of Holiday Season Dec 05 2016 
    Barrick Repurchases $595 Million of Corporate Loan Dec 02 2016 

    More From Other Websites
    Billionaire Rob Citrone’s Monster Q3 Buys: Kellogg, Macy’s, Activision-Blizzard, More Dec 04 2016
    Gundlach warns Trump trade is ‘losing steam’ and stocks have peaked Dec 02 2016
    Label Expansion May Boost Venclexta’s Growth Prospects Dec 02 2016
    What Do Analysts Recommend for Gilead Sciences Stock? Dec 02 2016
    Nelson: Optimistic about innovation possibly impacting ca... Dec 01 2016
    Valbenazine May Become a Leading Therapy for Tardive Dyskinesia Dec 01 2016
    Five ways to evaluate an Obamacare replacement plan Dec 01 2016
    What to expect from HHS Secretary nominee and Obamacare opponent Tom Price Dec 01 2016
    Why AbbVie Wants to Develop Anti-Tau Therapies Dec 01 2016
    Next-Generation Hepatitis C Therapy May Be AbbVie’s Growth Driver Nov 29 2016
    AbbVie’s Financial Guidance for 2017 Nov 29 2016
    Analysts say Juno's stock tumbles shouldn't spill over to Bluebird, Kite Pharma shares Nov 23 2016
    How Stocks and Bonds Reacted to Trump’s Victory Nov 22 2016
    Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios Nov 17 2016
    Leading Indicator, testing key breakout level! Nov 17 2016
    Is Immunotherapy the Next Hot Industry for Biotech Stock Investors? Nov 16 2016
    Biotech takes Trump presidency as a green light — and end to drug price worries Nov 16 2016
    5 Reasons to Buy 5 Low P/E Biotech ETFs Nov 14 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)